Montelukast Glenmark (Montelukast Sodium)

Montelukast Sodium selectively antagonizes the cysteinyl leukotriene receptor CysLT1. This blocks leukotriene D4 and related mediators from triggering bronchoconstriction, mucus production, vascular leakage and inflammatory cell recruitment, thereby improving breathing and reducing allergic symptoms.

The appropriate dose of Montelukast Glenmark is determined by the prescribing healthcare professional based on the patient’s age, condition and clinical response. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

The safety of Montelukast during pregnancy or lactation has not been definitively established. Healthcare providers weigh potential benefits against possible risks and may consider alternative therapies when appropriate. Patients should discuss their specific situation with their physician.

To request Montelukast Glenmark, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with allergic components or exercise‑induced symptoms, whereas inhaled therapies directly target airway inflammation and bronchospasm.

Montelukast Glenmark should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Montelukast Glenmark is taken orally, usually as a single tablet each day. It can be swallowed with or without food, according to the prescriber’s instructions. Consistency in timing helps maintain steady drug levels.

Serious risks include severe allergic reactions such as rash, angioedema or anaphylaxis, and neuropsychiatric events like depression, anxiety or suicidal thoughts. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Glenmark is contraindicated in individuals with known hypersensitivity to montelukast sodium or any of its excipients. It should be used with caution in patients with liver disease, psychiatric disorders, or those taking interacting medications.